Cadila Healthcare at the forefront of innovation in India, says analyst

2 June 2021
cadila-big

Cadila Healthcare (BOM: 532321) is among the leading players in India which focuses on bringing in-house developed innovative therapies for patients. Cadila Healthcare has developed a diversified COVID-19 portfolio among the Indian players through in-house development and licensing opportunities.

In line with this, the COVID-19 situation has put Cadila Healthcare at the forefront of innovation in India, says GlobalData, a data analytics and research company.

According to GlobalData’s ‘Pharmaceutical Intelligence Center’ (as of May 27, 2021), Cadila Healthcare’s COVID-19 portfolio includes one repurposed marketed drug and ‘seven in-house’ candidates in the pipeline, including two in Phase III, one each in Phase II and Phase I and three candidates in preclinical development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars